<p>Inflammatory bowel diseases: time of diagnosis, environmental factors, clinical course, and management – a follow-up study in a private inflammatory bowel disease center (2003–2017)</p>

Abstract

Background The governmental program of Brazilian Unified National Health System has already published studies on the incidence of inflammatory bowel diseases (IBD), but up until now, there have been no epidemiological studies in private centers in Brazil. However, these diseases tend to affect people from a higher socioeconomic class, mainly in the capital of MS state that has the third highest GDP in Brazil. Objectives The aim was to analyze an observational, descriptive study of an IBD database in a private center including: the side, behavior of the disease and medical management, the association of extra-intestinal manifestations, and the main clinical symptoms which led to the investigation and diagnosis of IBD. Patients and methods A cohort study was developed in which data of all patients with IBD were analyzed with SPSS software in a constructed electronic database. Results Of 329 patients, 212 (64.4%) had Crohn’s disease (CD) and 117 (35.6%) had ulcerative colitis (UC). Average age at diagnosis of CD was 36.19 (±14.33) and of UC was 41.61 (±15.37). An amount of 50.05% of the patients with CD and 72.7% ( P <0.001) with UC were female. We have observed that concerning the first symptoms, diahrrea and blood feces corresponded to 70% in UC while in CD 50% of the patients presented diahrrea with blood feces, loss of weight corresponded to 50% and only diahrrea 25%. ( P <0.001). Anti-TNFs corresponded to 56.2% being more frequent in CD 0.001%. CD patients used biologic therapy and antibiotics more frequently than those with UC. In conclusion, IBD is also frequent in private health care centers in Brazil; women are most affected. Symptoms such as diarrhea and bleeding, as well as diarrhea and weight loss, must be taken as warning signs to investigate for inflammatory disease. The use of biologic therapies is frequent in referral centers when patients have severe disease.

Impact of gastrointestinal symptoms on quality of life in MEN2

“…A high prevalence of GI symptoms in MEN2A patients has previously been reported, yet our cohort highlighted abdominal pain 85% ( n = 49), diarrhoea 85% ( n = 49) and constipation 75% ( n = 43). The burden of diarrhoea in MEN2A patients was comparable to untreated Crohn's disease (64%) or ulcerative colitis (89%) reported in other studies 13,14 . There was no difference in the severity of diarrhoea between people reporting high and normal calcitonin (mean score of 2 ± 1.16 vs. 2 ± 1.1).…”

Review of the epidemiology and burden of ulcerative colitis in Latin America

“… 16 , 33 The proportion of patients with a family history of IBD ranged from 2.5% in Barbados to 19.3% in Puerto Rico, 11 , 33 and the vast majority of patients were urban residents, ranging from 77.8% in Sergipe, Brazil to 97.4% in Mato Grosso do Sul, Brazil. 18 , 19 A low proportion of patients with UC were current smokers, ranging from 0.0% in Mexico City to 16.4% in Montevideo, Uruguay. 29 , 36 The majority of patients were non-smokers (ranging from 60.1% in Montevideo, Uruguay to 91.3% in Mexico City), with the exception of Sergipe, Brazil, in which the majority of patients (76.1%) were ex-smokers.…”

“… 36 Disease severity was only reported in 3 studies from Brazil, with moderate to severe UC accounting for 45.9–73.0% of all cases ( Figure 3 ). 15 , 18 , 19 …”

The Link between Oral and Gut Microbiota in Inflammatory Bowel Disease and a Synopsis of Potential Salivary Biomarkers

“…IBD affects multiple ethnic and racial groups, with onset of disease occurring throughout early adulthood between the ages of 20-40 [9][10][11] with approximately 0.4-0.6% of cases being reported globally [12,13]. While data is still lacking for many developing countries, increases in IBD prevalence appears to be paralleled with increasing development index [13] as the incidence of UC is highest in North America with 16.4 new cases per 100,000 people annually and 16.7 per 1000 people in Canada [8].…”